Literature DB >> 12482944

Distribution of nitric oxide synthase in normal and cirrhotic human liver.

Lance McNaughton1, Lakshmi Puttagunta, Maria Angeles Martinez-Cuesta, Norm Kneteman, Irvin Mayers, Redwan Moqbel, Qutayba Hamid, Marek W Radomski.   

Abstract

Chronic liver disorders represent a serious health problem, considering that 300 million people worldwide are hepatitis B virus carriers, and 8,000-10,000 patients per year, in the U.S. alone, die as a result of liver failure caused by hepatitis C infection. Nitric oxide synthase (NOS) regulates hepatic vasculature; however, the patterns of expression and activity of NOS proteins in healthy and diseased human livers are unknown. Sections of diseased (n = 42) and control livers (n = 14) were collected during orthotopic liver transplants and partial hepatectomy. The diseased sections included alcoholic cirrhosis, viral hepatitis, cholestasis, acute necrosis, and uncommon pathologies including alpha(1)-anti-trypsin disorder. The endothelial NOS (eNOS), inducible NOS (iNOS), and neuronal NOS (nNOS) were studied by using the citrulline assay, Western immunoblot, immunohistochemistry, and in situ hybridization. The systemic generation of plasma NO metabolites was measured by HPLC. In control livers, Ca(2+)-dependent and -independent NOS activities were identified by Western analysis as eNOS and iNOS, respectively. The eNOS was uniformly distributed in the hepatocytes and also detected in the endothelium of hepatic arteries, terminal hepatic venules, sinusoids, and in biliary epithelium. The iNOS was detected in hepatocytes and localized mainly in the periportal zone of the liver acinus. This pattern of distribution of eNOS and iNOS in normal liver was confirmed by in situ hybridization. In diseased livers, there was a significant increase in Ca(2+)-independent NOS with the corresponding strong appearance of iNOS in the cirrhotic areas. The eNOS was translocated to hepatocyte nuclei. Thus, eNOS and iNOS proteins are differentially expressed in healthy human liver, and this expression is significantly altered in cirrhotic liver disorders.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12482944      PMCID: PMC139286          DOI: 10.1073/pnas.0134112100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  Hepatic expression of inducible nitric oxide synthase transcripts in chronic hepatitis C virus infection: relation to hepatic viral load and liver injury.

Authors:  S Mihm; A Fayyazi; G Ramadori
Journal:  Hepatology       Date:  1997-08       Impact factor: 17.425

2.  Expression and activity of nitric oxide synthases in human airway epithelium.

Authors:  D N Watkins; D J Peroni; K A Basclain; M J Garlepp; P J Thompson
Journal:  Am J Respir Cell Mol Biol       Date:  1997-06       Impact factor: 6.914

3.  Hepatitis B virus X protein transactivates the inducible nitric oxide synthase promoter.

Authors:  M J Amaro; J Bartolomé; V Carreño
Journal:  Hepatology       Date:  1999-03       Impact factor: 17.425

4.  Nitric oxide synthase activity is increased in relation to the severity of liver dysfunction.

Authors:  H F Galley; D Coomansingh; N R Webster; P W Brunt
Journal:  Clin Sci (Lond)       Date:  1998-09       Impact factor: 6.124

5.  VEGF induces nuclear translocation of Flk-1/KDR, endothelial nitric oxide synthase, and caveolin-1 in vascular endothelial cells.

Authors:  Y Feng; V J Venema; R C Venema; N Tsai; R B Caldwell
Journal:  Biochem Biophys Res Commun       Date:  1999-03-05       Impact factor: 3.575

6.  Nitric oxide blocks bile canalicular contraction by inhibiting inositol trisphosphate-dependent calcium mobilization.

Authors:  J F Dufour; T J Turner; I M Arias
Journal:  Gastroenterology       Date:  1995-03       Impact factor: 22.682

7.  Molecular cloning and expression of inducible nitric oxide synthase from human hepatocytes.

Authors:  D A Geller; C J Lowenstein; R A Shapiro; A K Nussler; M Di Silvio; S C Wang; D K Nakayama; R L Simmons; S H Snyder; T R Billiar
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

8.  The role of nitric oxide and metalloproteinases in the pathogenesis of hyperoxia-induced lung injury in newborn rats.

Authors:  A Radomski; G Sawicki; D M Olson; M W Radomski
Journal:  Br J Pharmacol       Date:  1998-12       Impact factor: 8.739

9.  Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia.

Authors:  C Guarner; G Soriano; A Tomas; O Bulbena; M T Novella; J Balanzo; F Vilardell; M Mourelle; S Moncada
Journal:  Hepatology       Date:  1993-11       Impact factor: 17.425

10.  Increased nitric oxide synthesis and inducible nitric oxide synthase expression in patients with alcoholic and non-alcoholic liver cirrhosis.

Authors:  A Sánchez-Rodríguez; M Criado; A M Rodríguez-López; A Esteller; A Martín de Arriba; J M López-Novoa
Journal:  Clin Sci (Lond)       Date:  1998-06       Impact factor: 6.124

View more
  44 in total

1.  Effects of neuronal nitric oxide synthase inhibition on resting and exercising hindlimb muscle blood flow in the rat.

Authors:  Steven W Copp; Daniel M Hirai; Peter J Schwagerl; Timothy I Musch; David C Poole
Journal:  J Physiol       Date:  2010-02-22       Impact factor: 5.182

2.  eNOS deletion impairs mitochondrial quality control and exacerbates Western diet-induced NASH.

Authors:  Ryan D Sheldon; Grace M Meers; E Matthew Morris; Melissa A Linden; Rory P Cunningham; Jamal A Ibdah; John P Thyfault; M Harold Laughlin; R Scott Rector
Journal:  Am J Physiol Endocrinol Metab       Date:  2019-07-30       Impact factor: 4.310

3.  Inducible nitric oxide synthase activity contributes to the regulation of peripheral vascular tone in patients with cirrhosis and ascites.

Authors:  J W Ferguson; A R Dover; S Chia; N L M Cruden; P C Hayes; D E Newby
Journal:  Gut       Date:  2005-11-18       Impact factor: 23.059

4.  Hepatoprotective effect of nitric oxide in experimental model of acute hepatic failure.

Authors:  Marek Saracyn; Marek Brytan; Robert Zdanowski; Tomasz Ząbkowski; Przemysław Dyrla; Janusz Patera; Stanisław Wojtuń; Wojciech Kozłowski; Zofia Wańkowicz
Journal:  World J Gastroenterol       Date:  2014-12-14       Impact factor: 5.742

5.  Preventive effects of dietary walnuts on high-fat-induced hepatic fat accumulation, oxidative stress and apoptosis in mice.

Authors:  Youngshim Choi; Mohamed A Abdelmegeed; Byoung-Joon Song
Journal:  J Nutr Biochem       Date:  2016-09-22       Impact factor: 6.048

6.  Expression and activity of inducible nitric oxide synthase and endothelial nitric oxide synthase correlate with ethanol-induced liver injury.

Authors:  Guang-Jin Yuan; Xiao-Rong Zhou; Zuo-Jiong Gong; Pin Zhang; Xiao-Mei Sun; Shi-Hua Zheng
Journal:  World J Gastroenterol       Date:  2006-04-21       Impact factor: 5.742

7.  Hybrid inhibitor of peripheral cannabinoid-1 receptors and inducible nitric oxide synthase mitigates liver fibrosis.

Authors:  Resat Cinar; Malliga R Iyer; Ziyi Liu; Zongxian Cao; Tony Jourdan; Katalin Erdelyi; Grzegorz Godlewski; Gergő Szanda; Jie Liu; Joshua K Park; Bani Mukhopadhyay; Avi Z Rosenberg; Jeih-San Liow; Robin G Lorenz; Pal Pacher; Robert B Innis; George Kunos
Journal:  JCI Insight       Date:  2016-07-21

8.  Intensive insulin therapy protects the endothelium of critically ill patients.

Authors:  Lies Langouche; Ilse Vanhorebeek; Dirk Vlasselaers; Sarah Vander Perre; Pieter J Wouters; Kristin Skogstrand; Troels K Hansen; Greet Van den Berghe
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

9.  Hepatocarcinogenesis driven by GSNOR deficiency is prevented by iNOS inhibition.

Authors:  Chi-Hui Tang; Wei Wei; Martha A Hanes; Limin Liu
Journal:  Cancer Res       Date:  2013-02-25       Impact factor: 12.701

10.  Reduced hepatic eNOS phosphorylation is associated with NAFLD and type 2 diabetes progression and is prevented by daily exercise in hyperphagic OLETF rats.

Authors:  Ryan D Sheldon; M Harold Laughlin; R Scott Rector
Journal:  J Appl Physiol (1985)       Date:  2014-02-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.